Cargando…
Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid
BACKGROUND: The manufacturing process of a new intravenous immune globulin (IVIG) 10% liquid product incorporates two dedicated pathogen safety steps: solvent/detergent (S/D) treatment and nanofiltration (20 nm). Ion-exchange chromatography (IEC) during protein purification also contributes to patho...
Autores principales: | Radomski, Kai Uwe, Lattner, Georg, Schmidt, Torben, Römisch, Jürgen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380692/ https://www.ncbi.nlm.nih.gov/pubmed/28236170 http://dx.doi.org/10.1007/s40259-017-0212-y |
Ejemplares similares
-
Intravenous immune globulin suppresses angiogenesis in mice and humans
por: Yasuma, Reo, et al.
Publicado: (2016) -
Recurrent Myocarditis Treated with Intravenous Immune Globulin and Steroids
por: Schwartz, Brandon H., et al.
Publicado: (2022) -
Intravenous Immune Globulin Uses in the Fetus and Neonate: A Review
por: Alsaleem, Mahdi
Publicado: (2020) -
Effectiveness and Safety of an Intravenous Immune Globulin (IVIG) Preparation in Post-exposure Prophylaxis (PEP) Against Measles in Infants
por: Kohlmaier, Benno, et al.
Publicado: (2021) -
Methylprednisolone versus intravenous immune globulin as an initial therapy in adult primary immune thrombocytopenia
por: Kim, Chul Hee, et al.
Publicado: (2019)